In the case of the B16 melanoma tumor model, we showed that CpG-Stat3 siRNA local treatment significantly potentiates the antitumor effects of PD-1 antibody, not only at the tumors that have received the treatment but also at non-treated distal tumors. The gene discussed is STAT3; the disease is neoplasm.